Semaglutide & Tirzepatide
Also known as: GLP-1 vs dual GIP/GLP-1 comparison entry
Semaglutide & Tirzepatide (also called GLP-1 vs dual GIP/GLP-1 comparison entry) is a research peptide in the GLP-1 Agonist class. This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- See individual products (~5–7 days)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GLP-1 receptorGIP receptor (tirzepatide)
Research summary
Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Each is approved on its own; the combination is not approved, and both labels say use with another GLP-1 receptor agonist is not recommended.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Semaglutide & Tirzepatide profile summarises 3 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Semaglutide & Tirzepatide dosage: no established human dose
Semaglutide and tirzepatide taken together have no established human dosage. No published or registered study has given the two together as one treatment. Each is FDA-approved on its own, with its own label: Wegovy (semaglutide) is escalated to a 2.4 mg once-weekly maintenance dose for weight reduction, and Zepbound (tirzepatide) starts at 2.5 mg once weekly and is escalated to 5, 10 or 15 mg once weekly. The trials that include both drugs compare them with each other rather than combine them.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: This entry pairs two approved incretin drugs: semaglutide, a GLP-1 receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist. Both act on the GLP-1 receptor. PubMed and ClinicalTrials.gov list many studies that include both drugs, but they compare them, enrol people taking either one, or follow people who switched from one to the other. None gives the two together as a combined treatment, so there is no dose, safety or outcome data for the combination.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established for the combination |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — semaglutide: FDA label, Wegovy, weight reduction in adultsFDA-approved label · FDA prescribing information for one component aloneStudied an analog, not Semaglutide & Tirzepatide itself | Adults with obesity, or overweight with a weight-related condition | 2.4 mg maintenance (1.7 mg alternative); maximum 7.2 mg, semaglutide alone | Subcutaneous | Once weekly | Escalated over 16 weeks, then continuous | Chronic weight management | WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed |
| Component (analog evidence) — tirzepatide: FDA label, Zepbound, weight reductionFDA-approved label · FDA prescribing information for one component aloneStudied an analog, not Semaglutide & Tirzepatide itself | Adults with obesity, or overweight with at least one weight-related comorbid condition | 5 mg, 10 mg or 15 mg maintenance; 2.5 mg starting dose, tirzepatide alone | Subcutaneous | Once weekly | Long term | Reduction and maintenance of body weight | ZEPBOUND (tirzepatide) injection — FDA prescribing information, DailyMed |
| Component (analog evidence) — SURPASS-2: tirzepatide compared with semaglutide, not combined (NCT03987919)Clinical trial · Phase 3 open-label randomised head-to-head trial of the components given separatelyStudied an analog, not Semaglutide & Tirzepatide itself | Adults with type 2 diabetes (n=1,879) | Tirzepatide 5 mg, 10 mg or 15 mg, or semaglutide 1 mg, each in a separate group | Subcutaneous | Once weekly | 40 weeks | Glycated haemoglobin change of -2.01, -2.24 and -2.30 points with tirzepatide 5, 10 and 15 mg against -1.86 with semaglutide; no group received both drugs | Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. |
Where sources disagree
- Each drug's approved dose comes from its own label, tested on its own. A dose of semaglutide or tirzepatide taken alongside the other is not a dose that was studied. See the Semaglutide and Tirzepatide profiles for each drug's labelled regimens.
- Both labels say the opposite of combining them. The Wegovy label says use with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. Tirzepatide also acts on the GLP-1 receptor.
- One UK physiology study, not yet recruiting (NCT07483801), plans one-off infusions of semaglutide and tirzepatide into an artery or vein to measure effects on blood vessels. It is not a treatment regimen and has no results.
- This entry is not sold as a combined vial in the shop listings checked, so there is no blend to reconstitute.
Handling & administration
- Injection Sites
- AbdomenThighUpper arm
- Timing Notes
- Each drug is injected once weekly on the same day each week, as its own label describes. The Wegovy and Zepbound labels say use with another GLP-1 receptor agonist is not recommended.
- Expected Onset
- 1–4 weeks (appetite), 8–12+ weeks (weight)
Sequence & molecular data
| Half-life | See individual products (~5–7 days) |
|---|---|
| Appearance | Prefilled pen (Rx) or research vials (where applicable) |
| Formulation | Prefilled Pen |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction. Tirzepatide activates both the GIP and GLP-1 receptors from a single peptide, with agonism weighted toward GIPR and biased signalling at GLP-1R that limits receptor desensitisation. The added GIP activity is the pharmacological difference, and head-to-head trial data in obesity has shown greater mean weight reduction with tirzepatide. Both are prescription medicines with class-typical gastrointestinal effects.
Origin
Two separate approved peptide drugs.
Targets
Studies
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes
- Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
Regulatory & research status
Semaglutide & Tirzepatide is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
Semaglutide & Tirzepatide side effects
Semaglutide & Tirzepatide has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Shared GI class effects
Contraindications
- Titrate slowly to manage GI effects; follow Rx guidance
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Semaglutide & Tirzepatide: frequently asked questions
What is Semaglutide & Tirzepatide?
Library comparison card for two FDA-approved weekly incretins: semaglutide (GLP-1) and tirzepatide (GIP/GLP-1). Not a single combination drug.
How does Semaglutide & Tirzepatide work?
This entry compares two approved incretin agents that differ in receptor coverage. Semaglutide is a mono-agonist at the GLP-1 receptor, acylated for weekly dosing, producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and centrally mediated appetite reduction.
Is Semaglutide & Tirzepatide FDA approved?
Yes. Semaglutide & Tirzepatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Semaglutide & Tirzepatide?
Reported half-life for Semaglutide & Tirzepatide is See individual products (~5–7 days). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Semaglutide & Tirzepatide banned in sport?
Semaglutide & Tirzepatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Semaglutide & Tirzepatide?
Compounds most often compared with Semaglutide & Tirzepatide include Amycretin, CagriSema, Cotadutide and Dulaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Wegovy labelExternal reference
- Zepbound labelExternal reference
- Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies — Endocrinol Diabetes Metab, 2025External reference
- Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes — JAMA Netw Open, 2025External reference
- Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis — Front Pharmacol, 2025External reference
Related research, comparisons & guides
- Tirzepatide vs. Semaglutide: What the Head-to-Head Trial Actually Found
- Tirzepatide Dosage Chart: Milligrams, and What They Are in Syringe Units
- Semaglutide Dosage Chart: The Escalation Steps and What They Are in Units
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Semaglutide & Tirzepatide preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Semaglutide & Tirzepatide profile is compiled from published literature (3 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Semaglutide & Tirzepatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →